Sumoylation and ubiquitinylation reversibly regulate the activity of transcription factors through covalent attachment to lysine residues of target proteins. We examined whether the Ets-1 transcription factor is modified by sumoylation and/or ubiquitinylation. Among four potential SUMO motifs in Ets-1, we identified lysines 15 and 227 within the LK 15 YE and IK 227 QE motifs, as being the sumoylation acceptor sites. Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1. We also found that Ets-1 is modified by K48-linked polyubiquitinylation independently of the sumoylation acceptor sites and is degraded through the 26S proteasome pathway, while sumoylation of Ets-1 does not affect its stability. Finally, sumoylation of Ets-1 leads to reduced transactivation and we demonstrated that previously identified critical lysine residues in Synergistic Control motifs are the sumoylation acceptor sites of Ets-1. These data show that Ets-1 can be modified by sumoylation and/or ubiquitinylation, with sumoylation repressing transcriptional activity of Ets-1 and having no clear antagonistic action on the ubiquitin-proteasome degradation pathway.
Introduction
Ets proteins are a family of transcription factors that share a highly conserved DNA-binding domain of approximately 80 amino acids, which specifically recognizes DNA sequence containing a GGAA/T core element. Ets-1 is the founding member of the ETS family and was found to play an important role in hematopoı¨etic development, angiogenesis and tumor progression (Wernert et al., 1992 (Wernert et al., , 1994 Bories et al., 1995; Muthusamy et al., 1995) . In addition to its C-terminal DNA-binding domain, Ets-1 contains an N-terminal transactivation domain, an original proteinprotein interaction domain (also called Pointed domain) that is shared by many ETS proteins and a central regulatory domain corresponding to exon VII (see Dittmer (2003) ).
The transcriptional activity of Ets-1 is known to be regulated by phosphorylation. The N-terminal sequence of Ets-1 is phosphorylated at threonine 38, within a MAPK phosphorylation motif activated following RAS activation. This phosphorylation enhances Ets-1 transcriptional activity (Rabault et al., 1996; Wasylyk et al., 1997; Slupsky et al., 1998; Paumelle et al., 2002) . In particular, we demonstrated that such activation of Ets-1 is triggered by hepatocyte growth factor/scatter factor (HGF/SF) through a RAS-ERK pathway, leading to transcriptional activation of Ets-1 and activation of promoters containing RAS-Responsive Elements constituted by combined EBS/AP1-binding sites (Fafeur et al., 1997; Paumelle et al., 2002) . Within the central regulatory domain, corresponding to exon VII, several Ets-1 serine phosphorylation sites have been identified. These serine residues (Ser ) are calcium-responsive phosphorylation sites and their phosphorylation inhibits its DNA binding activity (Rabault and Ghysdael, 1994; Cowley and Graves, 2000) .
Ubiquitinylation is another post-translational modification, which can reversibly regulate the activity of transcription factors (Herrera and Triezenberg, 2004) . Ubiquitin is a highly conserved protein of B9 kDa that becomes covalently attached to lysine residues of target proteins (Hershko and Ciechanover, 1998) . This occurs through a three-step process involving ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitinligating (E3) enzymes. In the best-characterized ubiquitin pathway, target proteins are tagged with ubiquitin chains linked via lysine 48 (K48) of ubiquitin. The produced polyubiquitinylated proteins are then targeted to and degraded by the 26S proteasome. Nonetheless, other ubiquitin modifications can occur, including polyubiquitinylation on other lysine residues of ubiquitin or monoubiquitinylation or multiple monoubiquitinylation (Haglund and Dikic, 2005) . It is now clear that ubiquitinylation functions not only for proteolysis, but also contribute to protein-protein interaction, endocytosis, DNA repair and transcriptional regulation (see (Hershko and Ciechanover, 1998) . To our knowledge, within the Ets family of transcription factors, only E1AF is known to be modified by polyubiquitinylation and to be degraded by the ubiquitin-proteasome dependent pathway (Takahashi et al., 2005) More recently, the small ubiquitin-related modifier (SUMO) has also been shown to reversibly modify many proteins (Matunis et al., 1996) . Three different SUMO proteins (B11 kDa) were identified in mammalian cells: SUMO-1, SUMO-2 and SUMO-3, with SUMO-2 and SUMO-3 having very high sequence similarity (Hay, 2005) . A tissue-specific SUMO-4 has also been recently identified, with sequence homology to SUMO-2/3 (Bohren et al., 2004) . SUMO modification consists in the covalent attachment of SUMO to a lysine residue, that generally lies within the consensus motif j-K-x-D/E (Rodriguez et al., 2001; Sampson et al., 2001) . The enzymes involved in the reversible conjugation of SUMO are similar to those mediating the ubiquitin conjugation (see (Hay, 2005) . SUMOs are activated by an E1 enzyme, Aos1/Uba2, and then are transferred to Ubc9, the E2 conjugation enzyme specific for SUMO (Desterro et al., 1997; Johnson and Blobel, 1997) and finally the rates of sumoylation of target proteins can be increased by E3 ligases, such as PIAS family members, RanBP2 or PC2. This modification is reversible by means of specific SUMO proteases, including SENP1, 2, 3 and 6 (Johnson, 2004) . SUMO modification appears to play a role in a variety of cellular processes including protein-protein interaction, subcellular localization, protein stabilization and transcriptional regulation (Dohmen, 2004) . A large number of SUMO target proteins have been identified, including several members of the Ets transcription factors family (Chakrabarti et al., 2000; Yang et al., 2003; Degerny et al., 2005; Leight et al., 2005; van den Akker et al., 2005; Wasylyk et al., 2005) . Recently, we reported that the ERM Ets protein is sumoylated and that sumoylation of ERM represses its transcriptional activity (Degerny et al., 2005) .
The transcriptional activity of Ets-1 is also regulated by interaction with other transcriptional factors and cofactors, allowing combinatorial control of gene expression and enhanced specificity of action of Ets-1 (Oikawa and Yamada, 2003) . Among these factors, Ubc9, initially known as an ubiquitin conjugating enzyme, was identified as a partner of Ets-1 able to bind both the N-terminal and the C-terminal part of Ets-1 (Hahn et al., 1997) . As Ubc9 is now known as an E2 enzyme involved in the conjugation of SUMO (Desterro et al., 1997; Johnson and Blobel, 1997) , we decided to examine whether Ets-1 can be sumoylated and/or ubiquitinylated.
Results

Ets-1 is a substrate for SUMO modification
To determine whether Ets-1 can undergo sumoylation, we analysed HEK293T cells that were transiently cotransfected with plasmids encoding HA-tagged mouse Ets-1 and His-tagged SUMO-1 or -2. Following transfection, cells were lysed, SUMO proteins were purified by nickel affinity chromatography and SUMOEts-1 conjugates were analysed by immunoblotting using an anti-HA antibody (Figure 1a ). In the absence of SUMO, Ets-1 was detected as a doublet with a major band of B58 kDa and a minor band of B62 kDa ( Figure 1a , middle panel). When Ets-1 and SUMO-2 were co-transfected, SUMO-modified Ets-1 products with molecular weight of B75 and 90 kDa and a minor one at B110 kDa were detected ( Figure 1a, top panel) . Their apparent increase in size of about 10-15 kDa is in agreement with addition of SUMO moieties. No bands were observed when cells were transfected with Ets-1 alone or together with SUMO-1. These results show that Ets-1 is modified by sumoylation.
To examine further the specificity of Ets-1 sumoylation, we analysed RK13, COS-7 and HEK293T cells that were transiently co-transfected with plasmids encoding HA-tagged Ets-1 and His-tagged SUMO-1, -2 or -3. Cells were then lysed and Ets-1 species were detected directly by immunoblotting using an anti-HA antibody (Figure 1b) . In RK13 cells, detection of high molecular weight bands was obtained with SUMO-1, -2 or -3, with the most prominent bands having a molecular mass of B75, 90 and 110 kDa. The similar SUMO-Ets-1 profile obtained with SUMO-1, -2 or -3 indicates that all SUMOs were capable to form polysumoylation chains at a single lysine site and/or multiple sumoylation at distinct lysine sites. In COS-7 and HEK293T cells (Figure 1b) , as well as in MDCK cells ( Figure 1c and data not shown), the higher molecular weight migrating bands of B75 and 90 kDa were obtained mainly in the presence of SUMO-2, indicating that in these cell types, SUMO-2 is more efficient than SUMO-1 and -3 in generating SUMO-Ets-1 conjugates. Similar results were obtained with another sumoylated substrate ERM, indicating that the ability and/or efficiency of SUMO-1, -2, -3 to sumoylate substrates can be cell type specific (Degerny et al., 2005) . These results show that Ets-1 can be modified by sumoylation in several cell types.
We next asked whether SUMO-2 modification of Ets-1 can be regulated by survival and/or stress stimuli. To this purpose, we used MDCK epithelial cells that we know to be responsive both to survival factors, such as HGF/SF (Fafeur et al., 1997) , and to stress stimuli, such as TNFa, H 2 O 2 or anisomycin (Reveneau et al., 2003; Tulasne et al., 2004) . Cells were transfected with Ets-1 and SUMO-2 and then treated by HGF/SF, TNFa, H 2 O 2 or anisomycin for 10 min. We found that H 2 O 2 treatment specifically stimulated SUMO-2 modification of Ets-1 (Figure 1c ). This effect of H 2 O 2 on SUMO-2 modification of Ets-1 was confirmed using the nickel affinity pull-down assay (data not shown). As HGF/SF is known to regulate Ets-1 activity (Paumelle et al., 2002) (Figure 2a ). Four Ets-1 mutants were then generated: K15R, K200R, K227R and K436R, with lysine to arginine point mutations.
Following co-transfection of HA-tagged Ets-1 wildtype (WT) or mutants and His-tagged SUMO-2 in COS-7 cells, cell lysates were subjected to nickel affinity pull-down assay and ETS1-SUMO-2 conjugates were detected by immunoblotting (Figure 2b ). Using WT Ets-1, we detected sumoylated forms of Ets-1 at B75 and B90 kDa, as well as at B110 kDa, as a minor form. Ets-1
IB HA (Ets-1) ) were transfected with plasmids expressing His-tagged SUMO-1 or 2 (0.7 mg) and HA-tagged Ets-1 (0.3 mg). SUMO-conjugated proteins were isolated by nickel affinity chromatography (Ni 2 þ ) and separated by SDS-PAGE. Ets-1 was detected by immunoblotting using an anti-HA antibody (top panel). The expression of Ets-1 in crude extract was also detected using an anti-HA antibody (middle panel). The filter was stripped and reprobed using an anti-Erk2 antibody to assess comparable loading (lower panel). The K200R and K436R Ets-1 mutants gave a profile similar to WT Ets-1, showing that they are not lysine sumoylation acceptor sites.
In contrast, the K15R and K227R Ets-1 mutants gave distinct profiles compared to WT Ets-1 (Figure 2b ). The 75 and the 90 kDa sumoylated forms of Ets-1 were not detected using the K15R and the K227R Ets-1 mutant, respectively, and the additional minor band of B110 kDa band disappeared using either the K15R or the K227R mutant, indicating that both K15 and K227 lysine residues are SUMO acceptor sites. Nonetheless, the specific disappearance of a sumoylated form of Ets-1 for K15 and K227 mutants at a different molecular weight was not expected (K15R and K227R leading to disappearance of the 75 and 90 kDa band, respectively). According to these molecular weights, it is possible that (Slupsky et al., 1998) and DNAbinding domain (DB, black) (Donaldson et al., 1996) are indicated. The transactivation domain (gray) and the central regulatory domain corresponding to exon VII are also indicated. (b) COS-7 cells (6 Â 10 5 ) were co-transfected for 24 h with WT Ets-1 or its KR mutants (0.6 mg) with or without His tagged SUMO-2 (1.4 mg). SUMO-conjugated Ets-1 proteins were isolated by nickel affinity chromatography (Ni 2 þ ) and detected using an anti-HA antibody (upper panel). Expression of Ets-1 was directly detected by immunoblotting in the whole cell lysate using an anti-HA antibody (lower panel). (c) RK13 cells (3 Â 10 5 ) were co-transfected with WT Ets-1 or its KR mutants (0.3 mg) with or without His tagged SUMO-1 or SUMO-2 (0.7 mg). Ets-1 species were detected by immunoblotting using an anti-HA antibody. (d) RK13 cells (3 Â 10 5 ) were transiently transfected with 1 mg plasmid including a fixed amount of Ets-1 plasmid (0.5 mg) and an increasing amount of SUMO-1 or SUMO-2 plasmids (0, 0.01, 0.05, 0.1, 0.2 and 0.5 mg). Ets-1 was detected by immunoblotting using anti-HA (top panel) antibody, SUMO-1 or SUMO-2 were detected by anti-SUMO-1 and anti-SUMO 2/3 antibody, respectively (middle panel). Filter was stripped and reprobed with an anti-Erk 2 antibody (lower panel).
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Z Ji et al the number of SUMO proteins attaching to K15 and K227 are distinct. Alternatively, both sites are similarly sumoylated and depending on the position of the lysine residue in the sequence of Ets-1, their SUMO modification alters differently their conformation, resulting in their migration in gel electophoresis at different molecular sizes. It should be noticed that this second possibility is commonly observed for SUMO-modified molecules and was recently established for the BKLF transcription factor, which similarly contains two lysine SUMO acceptor sites (Perdomo et al., 2005) . These results with individual mutants indicate that both K15 and K227 lysine residues are SUMO acceptor sites and this was confirmed using a K15R/K227R double mutant. Indeed, all sumoylated forms of Ets-1 were abolished using the K15R/K227R double mutant ( Figure 2b ) and similar results were obtained using either SUMO-1 or SUMO-2 in RK13 cells ( Figure 2c ). We further examined the contribution of each site by titrating levels of SUMO-1 and SUMO-2 in RK13 cells. The results showed that both K15 and K227 sites are modified by SUMO-1 or SUMO-2, with K15 having a higher affinity for SUMO than K227 ( Figure 2d ). These data show that Ets-1 is modified by monosumoylation at lysine residues 15 and 227.
Ets-1 sumoylation is regulated by enzymes of the SUMO pathway As Ubc9 has been identified as an interaction partner of Ets-1 (Hahn et al., 1997), we asked whether Ubc9 can enhance Ets-1 sumoylation. RK13 cells were cotransfected with expression plasmids encoding Ets-1, SUMO-2 and/or Ubc9 and the results were analysed by immunoblotting using an anti-HA antibody to detect Ets-1 species (Figure 3a ). Ubc9 was found to increase sumoylation of conjugated Ets-1 species, and in particular by leading to the generation of higher molecular weight forms of Ets-1 that may result form enhanced polysumoylation at K15 and K227 or from polysumoylation at multiple lysines, in addition to K15 and K227. To investigate whether Ubc9 directly affected Ets-1 sumolylation, we used the sumoylation-defective mutant, Ubc9-C93S, which abrogates the formation of a thioester bond between SUMO and Ubc9 (Desterro et al., 1997) . The Ubc9 inactive mutant was found to decrease strongly Ets-1 sumoylation. The double K15/ 227R mutant of Ets-1 was not modified by SUMO-2, neither when transfected alone nor when co-transfected with Ubc9 WT or mutant. These data show that Ubc9 acts as an E2 SUMO conjugating enzyme contributing to SUMO modification of Ets-1.
PIAS family proteins are conserved SUMO E3 ligases that can enhance SUMO conjugation of various targets (Schmidt and Muller, 2003) . In man, four PIAS genes have been identified (PIAS1, PIAS3, PIASx and PIASy) which encode proteins that share a similar domain structure, but differ in their specificity of interaction with other proteins. We investigated the possibility that PIASy can enhance Ets-1 sumoylation in RK13 cells. Cells were co-transfected with Ets-1 (WT or KR mutant), SUMO-2 and/or PIASy (WT or inactive W363A mutant), and the results were analysed by immunoblotting (Figure 3b ). Similarly to Ubc9, PIASy was found to increase sumoylation of conjugated Ets-1 species and to generate higher molecular weight forms of Ets-1 The double K15/227R mutant of Ets-1 was not modified by SUMO-2, neither when transfected alone nor when co-transfected with PIASy WT or mutant.
We then analysed whether PIASy can interact with Ets-1. Following their transfection, PIASy was immunoprecipitated using an anti-Flag antibody and the samples were immunoblotted using an anti-HA antibody to detect Ets-1. PIASy was found to interact with Ets-1, as well as with the K15R/K227R Ets-1 mutant (Figure 3c) , showing that PIASy interacts with Ets-1 independently of its SUMO acceptor sites. The fact that PIASy favors Ets-1 sumoylation and interacts with Ets-1 shows that PIASy acts as an E3 ligase for SUMO modification of Ets-1.
The SUMO pathway is reversible by means of specific isopeptidases, including SENP1 (Cheng et al., 2004) . We investigated the possibility that SENP1 can reverse Ets-1 sumoylation in RK13 cells. Cells were co-transfected with Ets-1 (WT or K15R/K227R mutant), SUMO-2 and/or SENP1 (WT or R360L/K631M mutant), and the results were analysed by immunoblotting. SENP1 was found to desumoylate all conjugated Ets-1 species, in contrast to its mutant version (Figure 3d ).
Ets-1 is ubiquitinylated independently of the SUMO modification sites SUMO and ubiquitin are covalently attached to lysine residues of target proteins and in some cases these posttranslational modifications occur at the same lysine residues (Desterro et al., 1998) . To investigate this, we first explored whether Ets-1 can undergo ubiquitinylation. HEK293T cells were co-transfected with HAtagged Ets-1 and His-tagged ubiquitin and then treated for 6 h with MG132, a proteasome inhibitor. Ubiquitinbinding proteins were purified by nickel affinity chromatography and Ets-1 was detected by immunoblotting using an anti-HA antibody. A ladder of higher molecular weight ubiquitinated Ets-1 products was detected only in the case of co-transfection of ubiquitin and Ets-1 (Figure 4a ). We then transfected cells with an ubiquitin K48R mutant, to check whether this protein profile correspond to polyubiquitinylation through K48 linkages. This mutant prevented formation of the ladder of higher molecular weight-ubiquitinylated Ets-1 products (Figure 4a) . A remaining ubiquitinylated-Ets1 conjugated band of about 65 kDa was detected, which can correspond to a single ubiquitin K48R mutant conjugated to Ets-1. By immunoblotting of the whole cell lysate, we noticed that co-expression of ubiquitin and Ets-1 yielded to an increase in Ets-1 signal detection. This result cannot be simply explained by a stabilization of Ets-1 ubiquitinylated forms in the presence of proteasome inhibitor, since a similar result was obtained in the absence of MG132, and was also obtained using MG101, another proteasome inhibitor ) were transfected with expression plasmids encoding WT or K15/227R mutant of Ets-1 (0.3 mg), His-SUMO-2 (0.7 mg), Flag-tagged Ubc9 (Ubc9 WT) or inactive mutant Ubc9/C93S (Ubc9 mut) (0.5 mg). Ets-1 was detected by immunoblotting using an anti-HA antibody (upper panel). The expression of either Ubc9 or Ubc9/C93S was detected with an anti-Ubc9 antibody, which also detected endogenous Ubc9 (middle panel). As only Ubc9 is Flag-tagged, Ubc9 migrated at a higher molecular weight than Ubc9-C93S. The filter was stripped and reprobed using an antiErk2 antibody (lower panel). (b) RK13 cells (3 Â 10 5 ) were co-transfected for 24 h with HA-tagged WT or K15/227R mutant of Ets-1 (0.3 mg) and Flag-tagged PIASy WT (PIASy WT) or inactive W363A mutant (PIASy mut) (0.05 mg) with or without SUMO-2 (0.5 mg). Ets-1 was detected by immunoblotting using an anti-HA antibody (top panel). The expression of WT or mutant PIASy was detected using an anti-Flag antibody (middle panel). The filter was stripped and reprobed using an anti-Erk2 antibody (lower panel). (c) RK13 cells (2 Â 10 6 ) were transfected for 24 h with HA-tagged wildtype Ets-1 (WT) or the K15R/K227R Ets-1 mutant (KR) (5 mg) alone or in combination with Flag-tagged PIASy (5 mg). Following immunoprecipitation of PIASy proteins with an anti-Flag antibody, Ets-1 proteins were detected using an anti-HA antibody (top panel). The expression of PIASy (Flag antibody) and Ets-1 (HA antibody) in whole cell lysate is also shown. The filter was stripped and reprobed using an anti-Erk2 antibody (lower panel). (d) RK13 cells (3 Â 10 5 ) were co-transfected for 24 h with HA-tagged WT or K15/227R mutant of Ets-1 (0.3 mg) and Flag-tagged SENP1 WT (SENP1 WT) or R360L/K631M mutant (SENP1 mut) (0.2 mg) with or without SUMO-2 (0.5 mg). Ets-1 was detected by immunoblotting using an anti-HA antibody (top panel). The expression of WT or mutant SENP1 was detected using anti-Flag antibody (middle panel). The filter was stripped and reprobed using an anti-Erk2 antibody (lower panel).
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(data not shown). Overall, our results show that Ets-1 is mainly modified by K48-linked polyubiquitinylation. As K48-linked polyubiquitinylation of a target protein represents a signal for its degradation by the 26S proteasome-dependent pathway (Hershko and Ciechanover, 1998) , we examined whether Ets-1 can be degraded by the proteasome. Under conditions of protein synthesis inhibition by cycloheximide (CHX), we checked the effect of the 26S proteasome inhibitor MG132 on Ets-1 stability. Results were analysed by immunoblotting (Figure 4b , left panel) and quantified (Figure 4b, right panel) . Protein level of Ets-1 was Ets-1 is a target for K48-linked ubiquitinylation and disruption of the sumoylation site does not prevent Ets-1 ubiquitinylation. (a) HEK293T cells (6 Â 10 5 ) were co-transfected with HA-tagged Ets-1 (0.6 mg) and His-tagged WT ubiquitin or its mutant version K48R (1.4 mg) for 24 h. Cells were then treated with 25 mM MG132 for 6 h. Ubiquitin-modified Ets-1 was purified by nickel affinity chromatography (Ni 2 þ ) and was detected by immunoblotting using an anti-HA antibody (top panel). The expression of Ets-1 in whole cell lysate was detected by immunoblotting using an anti-HA antibody (middle panel). The filter was stripped and reprobed using anti-Erk 2 antibody (lower panel). (b) COS-7 cells were transfected with HA-tagged Ets-1 for 24 h. The cells were then treated or not with 25 mM MG132 for 1 h, followed by addition of CHX (25 mg/ml) for the indicated times. At the end of the experiment, 50 mg of cell lysates were subjected to SDS-PAGE and Ets-1 was detected by immunoblotting using an anti-HA antibody (left panel) and chemiluminescence intensity was quantified (right panel). The filter was stripped and reprobed using an anti-Erk 2 antibody (lower panel). (c) HEK293T cells (6 Â 10 5 cells) were co-transfected with HA-tagged Ets-1 (WT or K15R, K200R, K227R, K436R or K15R/K227R mutants, 0.6 mg) and His-tagged ubiquitin (1.4 mg) for 24 h and then were treated by 25 mM MG132 for another 6 h. Ubiquitin-modified Ets-1 was purified and analyzed as described above (top panel). The expressions of Ets-1 (middle panel) and Erk 2 (lower panel) in cell lysate are also shown.
Sumoylation and ubiquitinylation of Ets-1 Z Ji et al higher in the presence of MG132, showing that Ets-1 is degraded by the 26S proteasome pathway.
We then assayed whether disruption of the lysine sumoylation acceptor sites prevented Ets-1 ubiquitinylation. We transiently co-transfected HEK293T cells with ubiquitin and WT Ets-1 or its corresponding mutants K15R, K200R, K227R, K436R or K15R/K227R. Ubiquitin-conjugated Ets-1 species were detected by nickel affinity pull down assay. We found that Ets-1 WT and KR mutants were ubiquitinylated at similar levels (Figure 4c) , showing that disruption of the Ets-1 sumoylation sites does not prevent Ets-1 polyubiquitinylation.
Effects of sumoylation on Ets-1 stability and subcellular localization We investigated whether SUMO modification can affect Ets-1 stability. Ets-1 WT or non-sumoylable mutant K15R/K227R were expressed in RK13 cells and then treated with CHX for various periods of time. Results were analysed by immunoblotting (Figure 5a ). Both Ets-1 WT and K15R/K227R mutant had a similar steady-state under CHX treatment, with a half-life of about 45 min. Nonetheless, we noticed a slight increase of the stability of the K15R/K227R mutant, indicating that these mutations affected Ets-1 stability.
We then compared the stability of non-sumoylated and sumoylated forms of Ets-1. SUMO-2 and Ets-1 WT were co-transfected in RK13 cells and were then treated with CHX for the indicated times. Results were analysed by immunoblotting (Figure 5b) . The sumoylated and non-sumoylated forms of Ets-1 had a similar steady state. These results show that SUMO modification of Ets-1 has no major effect on its stability.
We also asked whether sumoylation of Ets-1 modified its subcellular localization. MDCK cells were transfected with Ets-1 WT or mutant K15R/K227R with or without SUMO-2, and localization was performed using indirect immunoflorescence microscopy. Ets-1 WT or K15R/K227R mutant were detected in the nucleus. Overexpression of SUMO-2 did not affect significantly the nuclear localization of Ets-1 (Figure 5c ). We also found that H 2 O 2 treatment did not modify Ets-1 subcellular localization in the presence of SUMO-2 (data not shown). These results indicate that SUMO modification of Ets-1 does not affect its localization.
Effects of SUMO modification on Ets-1 transcriptional activity Sumoylation has been reported to affect the transcriptional activity of various transcription factors. We examined the effect of SUMO-2 on the transcriptional response to Ets-1 using a RAS-Responsive Element (RRE)-Luc reporter vector, which contains three combined Ets/AP1-binding sites in HEK293T cells. SUMO-2 was found to repress the transcriptional response to Ets-1 (Figure 6a) . Similar results were obtained with SUMO-1 in RK13 cells (data not shown). Conversely, we challenged the ability of Ets-1 WT and sumoylation mutants (K15R, K227R and K15R/ K227R) to transactivate this RRE-luc reporter vector. The Ets-1 single site sumoylation K15R and K227R mutants were more efficient in inducing a transcriptional response than WT Ets-1, and the double K15R/K227R mutant gave an additional increase of transcriptional response in HEK293T cells (Figure 6b) . Similar results were obtained in RK13 cells, with the single and double Ets-1 mutants leading to the same enhancement of a transcriptional response (Figure 6c ). We also examined distinct Ets-dependent reporter genes, that is the E74-luc reporter vector which contains three Ets-binding sites and the ICAM-1-luc reporter vector in which transcription is directed from the human ICAM-1 promoter containing two Ets-binding sites (de Launoit et al., 1998) . Enhancement of the transcriptional response using the double Ets-1 sumoylation mutant was observed for both reporter vectors (Figure 6d and data not shown). These results show that expression of SUMO represses a transcriptional response to Ets-1, while disruption of the Ets-1 SUMO modification sites enhance it.
We then investigated whether the transcriptional response to Ets-1 was modified by enzymes of the SUMO pathway. To this purpose, cells were cotransfected with Ets-1 WT or sumoylation mutant K15R/K227R and the inactive C93S mutant version of Ubc9 (Ubc9 mut) (Figure 6e ). While mutant Ubc9 enhanced the transcriptional response to Ets-1, it did not impair increased transcription by the sumoylation mutant K15R/K227R Ets-1, indicating that sumoylation activity of Ubc9 is involved in the transcriptional response to Ets-1. Nonetheless, in agreement with a previous report (Hahn et al., 1997) , we found that the WT version of Ubc9 both enhanced the transcriptional response to Ets-1 WT and K15R/K227R mutant (data not shown). It remains possible that Ubc9 in addition to its sumoylation activity can function as a co-activator in transcription and that these activities are separable, as previously demonstrated for the COUP-TF1 transcription factor (Kurihara et al., 2005) . To further examine the contribution of the enzymes of the SUMO pathway, we analysed the effect of the SENP1 protease, that we demonstrated to be effective in desumoylating Ets-1 (Figure 3d ). Cells were co-transfected with Ets-1 WT or sumoylation mutant K15R/K227R and the WT or inactive R360L/K631M mutant of SENP1 (Figure 6f ). While SENP1 WT enhanced the transcriptional response to Ets-1, its mutant version was ineffective. In contrast, SENP1 WT and inactive mutant did not impair increased transcription by the Ets-1 sumoylation mutant K15R/K227R. Thus, desumoylation of Ets-1 by means of a specific SUMO protease enhances its transcriptional activity, and this confirmed that the transcriptional activity of Ets-1 is inhibited by the SUMO pathway.
Discussion
Ets-1 transcriptional activity is known to be regulated by phosphorylation via RAS and Ca 2 þ -dependent protein kinase pathways (Rabault and Ghysdael, 1994; Rabault et al., 1996; Wasylyk et al., 1997; Slupsky et al., 1998; Cowley and Graves, 2000; Paumelle et al., 2002) . Here, we demonstrated that Ets-1 is also modified by other post-translational modifications, that is sumoylation and ubiquitinylation. Ets-1 is modified by sumoylation at lysines K15 and K227 and these residues are not required for its 48K-linked polyubiquitinylation. These modifications appear to distinctly regulate Ets-1 activity, with polyubiquitinylation regulating its protein stability and sumoylation reducing its transcriptional activity.
In the SUMO cycle, target proteins are reversibly conjugated with SUMO chains via isopeptide bonds, catalysed by the sequential actions of E1 activating enzyme (Uba2/Aos1), E2 conjugating enzyme (Ubc9) and E3 ligases (PIAS, RanBP2 or Pc2) (see (Hay, 2005) . As Ets-1 has been reported as a partner of Ubc9 (Hahn et al., 1997) , the only known E2 conjugation enzyme for SUMO (Desterro et al., 1997; Johnson and Blobel, 1997) , the possibility was raised that Ets-1 could be modified by sumoylation. Our data reveal that Ets-1 indeed undergoes SUMO modifications, with Ubc9 being able to enhance sumoylation of Ets-1. We also examined whether PIAS proteins can act as E3 ligases for SUMO modification of Ets-1, since these proteins can enhance SUMO conjugation of many transcription factors, including ETS transcription factors, such as Elk-1 (Yang and Sharrocks, 2005) and Net (Wasylyk et al., 2005) . Our data show that PIASy is able to interact and to enhance sumoylation of Ets-1. Finally, the SENP1 SUMO protease was found to desumoylate Ets-1 confirming that enzymes of the SUMO pathway are effective in modifying Ets-1. Although, these data demonstrated sumoylation of Ets-1 by enforced expression, we were not able to convincingly demonstrate endogenous sumoylation of Ets-1. As reported by others, we can mention that usually only a small fraction of the substrate, often o1%, is sumoylated at any given time, with possibly SUMO-cleaving enzymes rapidly desumoylating all conjugates (reviewed by Johnson (2004) PD in the sequence of Ets-1, we identified lysine residues K15 and K227 as being the effective SUMO acceptor sites. Indeed, the sumoylation profile of Ets-1 consisted in two major sumoylated Ets-1 bands having a molecular mass of B75 and B90 kDa and a minor band at B110 kDa and all these bands were abolished using the double Ets-1 K15R/K277R mutant. A recent structural study adds to the knowledge of recognition of SUMO by Ets-1 (Macauley et al., 2005) . These authors also identified K15 as being a SUMO-1 acceptor site in Ets-1. Using NMR spectroscopy, they show that the covalent attachment of SUMO-1 to the N-terminal part of Ets-1 (1-118) does not perturb the structure and dynamic properties of either SUMO-1 or of the flexible Nterminal segment of Ets-1, suggesting that SUMO-1 and Ets-1 may retain their independent conformation, when SUMO-1 is attached to K15.
The physiological mechanisms that regulate sumoylation of target proteins are far to be understood. Following short time exposure of epithelial cells either to growth factor stimulation or to various stresses, we found that only H 2 O 2 led to a strong stimulation of Ets-1 sumoylation by SUMO-2. This is in agreement with previous demonstrations that SUMO-2 is involved in cellular responses to environmental stress, such as oxidative stress (Degerny et al., 2005) or acute temperature fluctuation (Saitoh and Hinchey, 2000) . Whether this increased sumoylation of Ets-1 by H 2 O 2 has a functional consequence on Ets-1 activity, in particular in modifying resistance of cells to stress remains to be determined.
Both SUMO and ubiquitin are linked to proteins through lysine residues and some SUMO target proteins were also found to be modified by ubiquitin. By investigating this possibility, we found that in addition to be sumoylated, Ets-1 is ubiquitinylated. The ubiquitinylation profile of Ets-1 consisted in a ladder of high molecular weight-ubiquitinylated Ets-1 products. This ladder was prevented using an ubiquitin K48R mutant, showing that Ets-1 is mainly modified by K48-linked polyubiquitinylation. Of interest, it was found in some cases that target proteins can be modified by sumoylation and ubiquitinylation at the same lysine residue (Desterro et al., 1998; Hoege et al., 2002) . For example, IkB is modified at Lys 21 both by SUMO-1 and ubiquitin, and the SUMO-1 modified IkB cannot be ubiquitinylated and is resistant to proteasome-mediated degradation (Desterro et al., 1998) . These results demonstrated antagonistic action of SUMO-1 and ubiquitin modifications on IkB protein, with sumoylation stabilizing the target protein by competition with ubiquitin. We rather found that disruption of the Ets-1 sumoylation acceptor sites did not prevent Ets-1 polyubiquitinylation, showing that Ets-1 can be polyubiquitinylated independently of lysine residues 15 and 227. We further investigated whether sumoylation or ubiquitinylation of Ets-1 modified its protein stability. Ets-1 was protected from degradation by a 26S proteasome inhibitor, indicating that K48-linked polyubiquitinylated forms of Ets-1 were degraded through the 26S proteasome pathway. In contrast, we found no major effect of the sumoylation of Ets-1 on its stability, with the sumoylated forms of Ets-1 being degraded at a similar rate than non-sumoylated forms of Ets-1. Taken together, these data show that Ets-1 can be modified both by sumoylation and ubiquitinylation and we did not evidence an antagonistic effect of SUMO on the polyubiquitinylation or degradation of Ets-1.
Modification of transcription factor by SUMO is known to be an important regulation mechanism for the transcriptional activity of these targets. Sumoylation of transcription factors and co-factors inhibits transcription in most cases and activates transcription in others (Seeler and Dejean, 2003; Johnson, 2004; Muller et al., 2004) . We found that sumoylation of Ets-1 leads to reduced transcription, with the sumoylation defective mutants having a greater capacity to activate transcription than Ets-1. Of interest, we demonstrated that lysines K15 and K227 sumoylation sites in Ets-1 are the critical lysine sites previously identified in synergistic control (SC) motifs, which repress synergistic transcription from promoters containing multiple ETS-binding sites (Iniguez-Lluhi and Pearce, 2000) or combined ETS/ AP1 binding sites, as demonstrated in this study. It was commonly found that Ets-1 is a weak modulator of gene expression by itself, while its activity is greatly increased by interaction with partner proteins (Crepieux et al., 1994; Dittmer, 2003) . The proposed mechanisms involve interaction with either DNA-bound or non-DNAbinding transcription factors. Our present data show that modification of Ets-1 by sumoylation is an additional mechanism for regulating its transcriptional activity.
In conclusion, we have identified sumoylation and ubiquitinylation as two novel post-translational modifications for Ets-1. Sumoylation does not affect ubiquitinylation and protein stability, but does modulate transcriptional activity of Ets-1. Our data reflect the diversity of outcomes that can result from the action of these two modifiers.
Materials and methods
Cell culture, reagents and antibodies HEK293T, COS-7, MDCK and RK13 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen). Human recombinant HGF/SF and TNFa were purchased from PeproTech Inc (Rocky Hill, NJ, USA), Anisomycin and MG132 from Calbiochem (San Diego, CA, USA), H 2 O 2 from Merck (Eurolab, Fontenay, France) and CHX from ICN Biochemicals Inc. (Aurora, Ohio, USA). Anti-Flag M5 and anti-Flag M2 monoclonal antibody (SigmaAldrich Corporation, St Louis, MI, USA) were used for immunoblotting and immunoprecipitation, respectively. Anti-HA mouse monoclonal antibody was purchased from Babco (Richmond, CA, USA), SUMO-1 and SUMO-2/3 from Abgent (San Diego, CA, USA), and anti-Ubc9 and antiErk2 from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Plasmids
His 6 -SUMO-1, -2, -3 expression vectors and Flag-tagged Ubc9 and its C93S mutant (without tag) expression plasmids were a generous gift from Dr Ron Hay (University of St Andrew, St Andrews, UK). His-Ubiquitin (WT and K48R mutant) plasmids were a gift from Dr M Benkirane (IGH, Montpellier, France). PIASy plasmid was kindly provided by Dr Maria Estela Andres (Catholic University of Chile, Santiago, Chile) and the PIASy (W363A) inactive mutant was constructed using a QuickChange site-directed mutagenesis kit (Stratagene) and was verified by DNA sequencing. SENP1 WT and inactive mutant (R360L, K631M) expression vectors were kindly provided by Dr ETH Yeh (University of Texas-MD Anderson Cancer Center, Houston, TX, USA) (Cheng et al., 2004) . The murine Ets-1 expression vector (pcDNA3-HAEts-1 1À440 ) was previously described (Paumelle et al., 2002) . HA-tagged pcDNA3-Ets-1 K15R, K200R, K227R, K436R and K15R/K227R mutants, were constructed using the QuickChange site-directed mutagenesis kit and were verified by DNA sequencing.
Luciferase reporter vectors used were as follows: the RASResponsive Element (RRE)-Luc reporter contains three tandem copies of polyoma-virus enhancer derived sequence, with EBS/AP1-binding sites linked to the thymidine kinase promoter (Fafeur et al., 1997) ; the E74-Luc vector contains three E74 Ets-binding sites cloned upstream from the minimal thymidine kinase promoter (Janknecht and Nordheim, 1996) . The pSG5-bGal vector was used to normalize transfections. Transfection RK13, COS-7 and HEK293T cells were transfected by PEI (Exgen 500 reagent, Euromedex) according to manufacturer's instructions. MDCK cells were transfected with Lipofectamine (Invitrogen) as described previously (Tulasne et al., 1999) .
Immunoprecipitation and immunoblotting
For immunoprecipitation, 500 mg cell lysate were incubated with anti-Flag antibody at 41C for 4 h. The immune complexes were recovered with protein A sepharose (Amersham Biosciences, Piscataway, NJ, USA) at 41C for another 1 h. The immunoprecipitates were separated by sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by immunoblotting and blots were developed using enhanced chemiluminescence (Roche Molecular Biochemicals, Indianapolis, IN, USA), as described previously (Paumelle et al., 2002) . As necessary, blots were visualized using a 16-bit charge-coupled device (CCD) cooled camera (Gene Gnome; Syngene) and quantification was carried out using GeneTools software (Syngene, Frederick, MA, USA).
For detecting sumoylation of Ets-1 by immunoblotting, transfected cells were scrapped into 200 ml phosphate-buffered saline (PBS). After brief centrifuge, 100 ml supernatant were mixed immediately with 100 ml 2 Â Laemmli gel loading buffer (0.5 M Tris-HCl pH 6.8, 4.4% SDS, 20% glycerol, 2% 2-mercaptoethanol, and bromophenol blue in distilled/deionized water) and boiled for 5 min. Proteins were then separated by SDS-PAGE and immunoblotted using an anti-HA antibody. This procedure prevents action of isopeptidases and thus preserves SUMO modifications of target substrates.
Nickel affinity pull-down assay His-SUMO-Ets-1 or His-Ub-Ets-1 conjugates were purified by Nickel affinity pull down assay, as described previously (Degerny et al., 2005) . Briefly, following their transfection, cells were lysed in denaturing buffer (6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 0.01 M Tris-HCl, pH 8.0) and incubated with Ni 2 þ -NTA beads (Qiagen, Valencia, CA, USA) for 2-3 h at room temperature. The beads were washed twice with lysis buffer, three times with wash buffer containing 8 M urea, 0.1 M Na 2 PO 4 /NaH 2 PO 4 , 0.01 M Tris-HCl, pH 6.3, and once with PBS. Bound proteins were resuspended in Laemmli gel loading buffer and separated by SDS-PAGE, His-SUMO-Ets-1 or His-Ub-Ets-1 conjugates were detected by immunoblotting using the anti-HA antibody.
Immunofluorescence microscopy MDCK cells (5 Â 10 4 cells/24 mm-dish) were cultured for 1 day in DMEM-10% FCS on glass cover slips and were transfected by Lipofectamine. At 24 h after transfection, cells were fixed in 4% paraformaldehyde, then incubated for 2 h with 1:1000 diluted anti-HA antibody. This was followed by incubation for 1 h with 1:1000 diluted fluorescein-conjugated anti-mouse IgG (7 mg/ml). Cell nuclei were counterstained using Hoechst 33258.
Luciferase reporter gene assay Cells (1.5 Â 10 5 cells/well) were grown in DMEM-10% FBS and the next day transient transfections were performed using the PEI procedure with 150 ng of DNA/well including 25 ng of reporter vector, 10 ng of Ets-1 expression vectors and 10 ng of b-galactosidase expression vector. In each transfection, plates were incubated with the same amount of plasmid DNA, completed as necessary with the corresponding empty vector. Luciferase activity was determined 24 h after transfection and normalized with respect to the b-galactosidase activity, as described previously (Degerny et al., 2005) .
